Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01264731 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01264731 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 4 participants.
The verdict
NCT01264731, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to determine 1) the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.
Interventions
- DRUG Imiquimod
- BIOLOGICAL MELITAC 12.1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01264731
The ClinicalTrials.gov registry entry for NCT01264731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imiquimod is the first listed.
NCT01264731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01264731 about?
NCT01264731 is a clinical study titled "Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma". The purpose of the study is to determine 1) the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of melanoma metastasis, with or withou...
What is the current status of trial NCT01264731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01264731?
The interventions under investigation include: Imiquimod (DRUG), MELITAC 12.1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01264731?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.